Sheila Gujrathi, M.D.

Dr. Sheila Gujrathi is a seasoned biotech entrepreneur, physician executive, translational scientist, and drug developer. She currently serves as founder and CEO of Prana Therapies, founder and executive chair of the board of directors of Lila Biologics and Vidya Therapeutics, and director of Janux Therapeutics. Her prior roles include executive chair of Ventyx Biosciences (acquired by Eli Lilly), chair of Turning Point Therapeutics (acquired by Bristol Myers Squibb) and ADARx Pharmaceuticals, venture advisor to Orbimed, co-founder and CEO of Gossamer Bio, CMO of Receptos (acquired by Celgene Corp.), Immunology Therapeutic Head at Bristol Myers Squibb and Avastin franchise team leader at Genentech. Sheila received both her M.D. in the accelerated Honors Program in medical education and her B.S. in biomedical engineering with highest distinction from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women’s Hospital and Harvard Medical School and additional fellowship training in allergy and immunology at the University of California, San Francisco and Stanford University.